UB-421 and Optimized Background Regimen for Multi-drug Resistant HIV-1 Infection

This is a phase 3 study looking into the effectiveness of a drug called UB-421 in combination with other HIV treatments, for patients with multi-drug resistant HIV-1 infection. The goal is to find out if UB-421 can help reduce the amount of HIV virus in the blood when used with other medications. This is important because it could potentially offer a new treatment option for those who aren't responding well to current treatments. In this trial, participants are randomly assigned to receive either UB-421 or a placebo, along with their current HIV treatment regimen. The main outcome being measured is the change in the amount of HIV-1 RNA viral load, which is a way to assess how well the treatment is controlling the virus. The study compares this change between the group receiving UB-421 and the group receiving the placebo.